BUSM researchers part of multi-center study on cardiac amyloidosis

Researchers at Boston University School of Medicine (BUSM) have been part of a multicenter observational study called TRACS (Transthyretin Amyloidosis Cardiac Study) to help determine the health significance of a particular gene mutation which is commonly found in Black Americans.

The gene, transthyretin (TTR) and the mutation V122I, is seen in about four percent of African Americans or roughly 1.5 million people. The mutation is strongly associated with a condition called cardiac amyloidosis - a disorder where the abnormally mutated TTR protein deposits in the heart of affected individuals, causing the heart to not pump adequately and ultimately results in death. Cardiac amyloidosis due to this mutation is seen in older people, over the age of 60 years. Cardiac amyloidosis can be also be due to genetically normal TTR as well, which occurs for unclear reasons but is strongly associated with age and male gender.

The researchers enrolled 29 patients with TTR cardiac amyloidosis due to either the V122I mutation or those with genetically normal TTR, and observed them for roughly 16 months. They found that Black patients with the mutation only survived for a median of 26 months after diagnosis, and that certain measured parameters including by echocardiography, blood testing and fell during the study and were associated with survival. Quality of life determined by questionnaire also declined significantly. These findings currently appear online in the .

"This study is important because it establishes that carriers of V122I are at increased risk of death from cardiac once they reach an age where the disease is expressed (generally over the age of 60)," explained lead author Frederick L. Ruberg, MD, assistant professor of medicine and radiology at BUSM. According to Ruberg these findings provide an important foundation on which future studies using can be based. "If patients on the new drug live longer or decline more slowly than those in TRACS, that would suggest a beneficial effect to treatment," he added.

add to favorites email to friend print save as pdf

Related Stories

Study leads to a promising first-in-class drug candidate

Jul 21, 2009

Discoveries by Scripps Research Institute scientists have led to a promising new drug candidate--the first in its class--for patients with a genetic protein-misfolding disease. In results announced by the biopharmaceutical ...

Recommended for you

Do heart patients fare better when doctors away?

6 hours ago

Doctors joke that if you're going to have a heart attack, the safest place would be at a big national gathering of heart specialists. But a new study suggests some older hospitalized heart patients may fare better when these ...

Survival rates higher in obese heart failure patients

6 hours ago

Patients who were obese before developing heart failure lived longer than normal weight patients with the same condition according to a new study in the Journal of the American College of Cardiology that e ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.